APX was severely overvalued at $40+. Whilst severe, it's not...

APX was severely overvalued at $40+. Whilst severe, it's not hard to see why it has been sold off. Basically has not grown since 2019 with ebitda of $84m in 2019 and this year's ebitda guidance to make around the same and revenue growth has come to a grinding halt. We all know the issues it has faced over the last year and if the forward outlook is bleak for FY22...this will be a long road to recovery. Not trying to down ramp, just being realistic of where it is at. I am hoping its restructure and diversification efforts recently can help facilitate the next lift in top line growth. It has no excuses this time, they need to start executing and show evidence of growth again. Let's see how they go in its forward outlook this earnings season.